Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) – Pipeline Review, H1 2018’, provides in depth analysis on Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease, Immunology and Toxicology under development targeting Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

– The report reviews Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Sihuan Pharmaceutical Holdings Group Ltd

Teijin Pharma Ltd

ViroStatics srl

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Overview

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Companies Involved in Therapeutics Development

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Sihuan Pharmaceutical Holdings Group Ltd

Teijin Pharma Ltd

ViroStatics srl

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Drug Profiles

abemaciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T38 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trilaciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voruciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-2370 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-3287 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Dormant Products

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Discontinued Products

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Product Development Milestones

Featured News & Press Releases

Feb 15, 2018: Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE for the First-Line Treatment of Metastatic Breast Cancer

Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib

Jan 03, 2018: Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports

Dec 13, 2017: First-line Ribociclib Improves PFS in Pre- and Peri-menopausal Women with HR-positive, HER2-negative Advanced Breast Cancer

Dec 12, 2017: SMC has recommended Ibrance(palbociclib) for use within NHS Scotland for previously untreated HR+/HER2- metastatic breast cancer

Dec 11, 2017: Ibrance is accepted for restricted use within NHS Scotland

Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival

Dec 06, 2017: Kisqali first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer

Nov 23, 2017: Researchers at Washington University report: DiviTum can evaluate the biologic activity of blockbuster breast cancer drug after two weeks

Nov 16, 2017: Novartis Advanced Breast Cancer Drug Kisqali (ribociclib) is First Cancer Treatment Recommended by NICE Under Updated Cancer Appraisal Process

Nov 14, 2017: Novartis To Present Data on Breast Cancer Drug Ribociclib At Upcoming 40th Annual San Antonio Breast Cancer Symposium (SABCS)

Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer

Nov 06, 2017: G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response

Nov 03, 2017: Pancreatic cancer patients to benefit from breast cancer drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Beta Pharma Inc, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by G1 Therapeutics Inc, H1 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Pipeline by MEI Pharma Inc, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Onconova Therapeutics Inc, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2018

Pipeline by Teijin Pharma Ltd, H1 2018

Pipeline by ViroStatics srl, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports